Antipsychotics and Metabolic Syndrome
NCT00636753 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2010-07-30
Summary
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and quality of life.
Conditions
- Metabolic Syndrome
Sponsors & Collaborators
-
Glostrup University Hospital, Copenhagen
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-09-30
- Primary Completion
- 2009-07-31
Countries
- Denmark
Study Locations
More Related Trials
-
AP Metabolism Transcriptomics
NCT06814314 ·Status: RECRUITING
-
Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
NCT06326840 ·Status: COMPLETED ·Phase: NA
-
Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine
NCT00617058 ·Status: TERMINATED ·Phase: PHASE2
-
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124 ·Status: WITHDRAWN ·Phase: PHASE4
-
PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
NCT05033119 ·Status: COMPLETED
-
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
NCT00806234 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients
NCT01206153 ·Status: COMPLETED ·Phase: PHASE4
-
Do Antidepressants Induce Metabolic Syndromes METADAP Study
NCT00526383 ·Status: COMPLETED ·Phase: NA
-
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
NCT00625170 ·Status: COMPLETED ·Phase: NA
-
A Prospective Study to Assess Metabolic Changes in Children and Adolescents Treated With Atypical Antipsychotics
NCT00480168 ·Status: COMPLETED
-
Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients
NCT02644577 ·Status: COMPLETED ·Phase: PHASE4
-
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
NCT00617240 ·Status: COMPLETED ·Phase: PHASE2
-
Metabolic Side-effects for Second-generation Antipsychotics
NCT01280396 ·Status: COMPLETED
-
Metformin for Weight Loss in Schizophrenia
NCT01177709 ·Status: TERMINATED ·Phase: NA
-
Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment
NCT00699530 ·Status: WITHDRAWN
-
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT04892199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Antipsychotics and Blood Vessel Function
NCT00585273 ·Status: COMPLETED
-
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
NCT00794963 ·Status: TERMINATED ·Phase: NA
-
Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction
NCT02447835 ·Status: COMPLETED ·Phase: PHASE1
-
Monitoring and Management for Metabolic Side Effects of Antipsychotics
NCT01875861 ·Status: COMPLETED ·Phase: NA
-
Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics
NCT00845936 ·Status: UNKNOWN ·Phase: PHASE4
-
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
NCT00809536 ·Status: TERMINATED ·Phase: PHASE1
-
Metabolic Effects of Antipsychotics in Children
NCT00205699 ·Status: COMPLETED ·Phase: PHASE4
-
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population
NCT04395326 ·Status: RECRUITING
-
Anti-psychotic Medication (Stable Dose) Weight Loss Study
NCT01272765 ·Status: WITHDRAWN ·Phase: PHASE2